Skolkovo and Promomed will get involved in the development of components for new medicines

Promomed 17 June 2022

Skolkovo Foundation and Promomed Group have agreed on joint projects in the field of biotechnology, molecular modeling, development of new dosage forms and components for them. The cooperation agreement was signed at the St. Petersburg International Economic Forum, the press service of Skolkovo Foundation reported on Friday.


«A new era in medicine has arrived: biotechnologies, RNA therapy, domestic substances of the highest quality are the response to the challenges of today. We will take up these challenges together with the leader in innovations, the Skolkovo Foundation. We see great prospects in joint work on the modeling of candidate molecules for medicinal products, the development of methods for the synthesis of pharmaceutical substances; optimization and improvement of production processes of APIs and finished dosage forms and in other areas,» said Petr Bely, chairman of the Board of Directors of Promomed Group, whose words are quoted in the news story.

According to the Foundation, a research and development center (R&D center) can be established on the basis of the Technopark-Mordovia to develop cooperation. Its will conduct and coordinate preclinical and clinical studies needed to further commercialize the developed products. According to Igor Drozdov, Chairman of the Board of the Skolkovo Foundation, the project will contribute to the achievement of the Russian Federation's import independence in the field of creating domestic medicines.

«One of the priorities of the state program «Development of the pharmaceutical and medical industry» is import independence. Skolkovo aims at this task within the framework of cooperation with leading domestic pharmaceutical companies. We are confident that the partner center based on our regional operator in Mordovia will be very useful in the creation of medicines for the population of our country,» Drozdov stressed.


About the companies

Skolkovo, Russia's largest innovation center, plays a significant role in strengthening the foundation of the national economy. In 2021, the revenue of Skolkovo residents increased by almost 55% compared to 2020 and amounted to 247.8 billion rubles. As of May 1, 2022, the number of Skolkovo resident startups exceeded 3,300. The number of jobs in the ecosystem is rapidly approaching 70 thousand.


Promomed Group is a Russian pharmaceutical company engaged in the development, production and promotion of medicines. Promomed's portfolio includes more than 200 medicinal products, 80% of which are included in the list of vital and essential drugs. Developments of Promomed Group are aimed at fighting infections, and are also used for the treatment of cancer, neurological and endocrinological diseases. The company is working on the formation of a special anti-COVID portfolio. Now it is represented by such products as Esperavir, Areplivir, Enoparin, Radamin viro and others.

Sourse: www.tass.ru